Comparison of prolactin level, sexual function, body mass index, and liver function tests in patients using depot antipsychotics

Year 2022, Volume: 47 Issue: 3, 1172 - 1178, 30.09.2022

Gülay Taşcı , Filiz Özsoy

https://doi.org/10.17826/cumj.1128200

Abstract

Purpose: In this study, it was aimed to compare sexual dysfunctions, body mass index, liver function tests and prolactin levels in patients using long-acting antipsychotic drug forms (depot paliperidone palmitate, risperidone depot and zuclopenthixol depot).
Materials and Methods: Patients diagnosed with schizophrenia and receiving long-acting antipsychotic therapy were included in this study. Demographic data form, Positive and Negative Syndrome Scale (PANSS), Calgary Depression in Schizophrenia Scale (CDSS), and Arizona Sexual Experiences Scale (ASEX) were administered to all participants. Venous blood samples were obtained from all participants to evaluate urea, creatinine, liver function tests, cholesterol and prolactin levels.
Results: 95 patients were included in the study. Of those included, 79 (83.2%) were men and 16 (16.8%) were women. The mean age of all patients was 36.77±10.24 years. The mean body mass index was 27.06±4.95 kg/m2. There was no difference between the groups in terms of ASEX and CDSS scores. The prolactin level was found to be higher in patients using paliperidone depot than in patients using zuclopenthixol depot.
Conclusion: According to our results, prolactin values that affect sexual functions should be considered in patients using long-acting antipsychotics, even if the patients do not show any symptoms. Further researches should be conducted on the effects of long-acting antipsychotic use on both prolactin values and other laboratory parameters.

Keywords

Long-acting antipsychotic drugs, sexual function, prolactin, liver function tests

Depo antipsikotik kullanan hastalarda prolaktin düzeyi, cinsel fonksiyon, vücut kitle indeksi ve karaciğer fonksiyon testlerinin karşılaştırılması

Abstract

Amaç: Bu çalışmada uzun etkili antipsikotik ilaç formları (uzun etkili paliperidon palmitat, risperidon depo ve zuklopentiksol depo) kullanan hastalarda cinsel işlev bozuklukları, vücut kitle indeksi, karaciğer fonksiyon testleri ve prolaktin düzeylerinin karşılaştırılması amaçlanmıştır.
Gereç ve Yöntem: Bu çalışmaya şizofreni tanılı ve uzun etkili antipsikotik tedavisi alan hastalar dahil edildi. Tüm katılımcılara demografik veri formu, Pozitif ve Negatif Sendrom Ölçeği (PANSS), Calgary Şizofrenide Depresyon Ölçeği (CŞDÖ) ve Arizona Cinsel Yaşantılar Ölçeği (ACYÖ) uygulandı. Ardından üre, kreatinin, karaciğer fonksiyon testleri, kolesterol ve prolaktin düzeylerini değerlendirmek için venöz kan örnekleri alındı.
Bulgular: Çalışmaya 95 hasta dahil edildi. Dahil edilenlerin 79’u erkek (%83.2) ve 16’sı kadındı (%16.8). Tüm hastaların yaş ortalaması 36.77±10.24 yıl idi. Vücut kitle indeksleri ortalaması ise 27.06±4.95 kg/m2 idi. Gruplar arasında ACYÖ ve CŞDÖ skorları açısından farklılık saptanmadı. Prolaktin değeri paliperidon depo kullanan hastalarda zuklopentiksol depo kullanan hastalardan yüksek olarak hesap edilmiştir.
Sonuç: Sonuçlarımıza göre cinsel işlevleri etkileyen prolaktin değerleri, hastalar semptom belirtmese de uzun etkili antipsikotik kullanan hastalarda göz önünde bulundurulmalıdır. Uzun etkili antipsikotik kullanımının hem prolaktin değerleri hem de diğer laboratuvar parametrelerine olan etkileri konusunda ileri araştırmalar yapılmalıdır.

Keywords

Şizofreni, depo antipsikotik ilaçlar, prolaktin, karaciğer fonksiyon testleri, üre, kreatinin.

References

• 1. Öztürk O, Uluşahin N. Ruh Sağlığı ve Bozuklukları. 13. Baskı. Ankara: Nobel Tıp Kitapevi; 2015. p.189-261.
• 2. Gaebel W, Zielasek J. Schizophrenia in 2020: Trends in diagnosis and therapy. Psychiatry Clin Neurosci. 2015; 69(11): 661-673.
• 3. Sacchetti E, Grunze H, Leucht S, Vita A. Longacting injection antipsychotic medications in the management of schizophrenia. Evidence-based Psychiatric Care. 2015;1:27-36.
• 4. Miyamoto S, Wolfgang Fleischhacker W. The use of long-acting injectable antipsychotics in schizophrenia. Curr Treat Options Psychiatry. 2017;4:117-26. 5. Olivares JM, Pinal B, Cinos C. Comparisons of long-acting antipsychotics injection and oral antipsychotics in schizophrenia. Neuropsychiatry. 2011;1:275-89.
• 6. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychatr Scand. 1987;76(334).
• 7. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290-99.
• 8. İnanç L, Özdemir AD, Güleç H, Semiz ÜB. Şizofreni ve bipolar bozukluk hastalarında depo antipsikotik kullanmanın etkinliği ve güvenirliği. Cukurova Med J. 2018; 43(Ek 1): 38-43.
• 9. Montejo AL, Majadas S, Rico-Villademoros F, LLorca G, De La Gándara J, Franco M, et al. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sexual Med. 2010; 7(10), 3404-3413.
• 10. Montejo AL, Montejo L, Baldwin DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry, 2018; 17(1): 3-11.
• 11. Aykut DS. Comparison of paliperidone palmitate and second-generation oral antipsychotics in terms of medication adherence, side effects, and quality of life. J Clin Psychopharmacol. 2019; 39(1): 57-62.
• 12. Hayhurst KP, Drake RJ, Massie JA, Dunn G, Barnes TRE, Jones PB, et al. Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Europ Psychiatry. 2014; 29(3):191-196.
• 13. Sathienluckana T, Tiangpattanawong P, Chaiyasukthananoan K, Jittayanan P, Sawetwangsing H, Puchsaka P. Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia. Schizop Res Treat. 2021; 8403986.
• 14. Aggarwal NK, Sernyak MJ, Rosenheck RA. “Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications,” J Clin Psychopharmacol. 2012; 32(3): 323-328.
• 15. Suzuki H, Hibino H, Inoue Y, Takaya A. “Comparisons of the effects of long-acting injectable monotherapy and combination therapy of long-acting injectable treatment with oral antipsychotics on treatment retention in patients with chronic schizophrenia,” Asian J Psychiatry. 2018; 39: 112- 113.
• 16. Yang KC, Liao YT, Yang YK, Lin, SK, Liang CS, Bai YM. “Evidence-based expert consensus regarding longacting injectable antipsychotics for schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN),” CNS Drugs. 2021; 35(8): 893-905.
• 17. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988; 23(1):99-110.
• 18. Kostakoğlu AE, Tiryaki A, Göğüş A. Pozitif ve negatif sendrom ölçeğinin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Türk Psikoloji Derg. 1999; 14:23-32.
• 19. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res. 1994; 11: 239-244.
• 20. Oksay S, Aksaray G, Kaptanoğlu C, Bal C. Calgary Depresyon Ölçeği’nin şizofreni hastalarında geçerlik ve güvenirlilik çalışması. Türk Psikiyatri Derg. 2000; 11:278-284.
• 21. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno AM, Delgado PD, McKnnight MK, Manber R . The Arizona Sexual Experience Scale (ASEX): Reliability and Validity. J Sex Marital Ther. 2006; 26 (1): 25
• 22. Soykan A. The reliability and validity of Arizona sexual experiences scale in Turkish ESRD patients undergoing hemodialysis. Int J Import Res. 2004; 16: 531-534.
• 23. Olivares JM, Pinal B, Cinos C. Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia. Neuropsychiatry. 2011; 1(3): 275.
• 24. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore, L., Valley, D., ... & Liang, M. H. (2011). Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine, 364(9), 842-851.
• 25. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2013;2
• 26. Zhang F, Si T, Chiou CF, Harris AW, Kim CY, Jahagirdar P, et al. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatric Dis Treat. 2015; 11: 657.
• 27. Sliwa JK, Bossie CA, Fu DJ, Turkoz I, Alphs L. Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Dis Treat. 2012; 8: 375.
• 28. Bossie CA, Fu DJ, Sliwa JK, Alphs L, Ma YW. Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. Ther Adv Psychopharmacol. 2011; 1(4): 111-124.
• 29. Montalvo I, Ortega L, López X, Solé M, Monseny R, Franch J, et al. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Int Clin Psychopharmacol. 2013; 28(1): 46-49.
• 30. Martínez‐Giner G, Giménez‐De Llano E, Romero‐Rubio D, Abad‐Pérez MJ, Sánchez‐Martínez V. Sexual dysfunction in people treated with long‐acting injectable antipsychotics in monotherapy or polypharmacy: a naturalistic study. Int J Mental Health Nurs. 2022; 576-590.
• 31. Martın JC, Acu~na MJ, Labrador J, Blanco M, Casas C. Sexual dysfunction factors in patients withschizophrenia treated with second generationantipsychotics: Not only prolactin. Actas Espanolas DePsiquiatria. 2018; 46(6): 217-225.
• 32. Kirino E. Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. Annal General Psychiatry. 2017; 16(1): 1-7.
• 33. Zhao S, Wang X, Qiang X, Wang Hui MM, Jian MG, Maolei Shen MM, et al. Is there anassociation between schizophrenia and sexual dysfunctionin both sexes? A systematic review and meta-analysis. J Sex Med. 2020; 17(8): 1476-1488.
• 34. Uribe ES, Navarro FC, Medrano AFG, Cervantes KIG, Villalobos NAA, Rocha VDA, et al. Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis. J Psychiatric Res. 2020; 129: 222-233.